Anika Therapeutics

We are Anika Therapeutics, a global medical technology company at the forefront of pain management, tissue regeneration and wound healing. We are committed to delivering innovative medical solutions that help patients feel better faster, look and feel younger and remain active. With over 7 million procedures performed over the past twenty years utilizing our proprietary technology, Anika is helping individuals all over the world return to life naturally.
We are innovators and creators. We value strong discipline and exceptional focus from our personnel, and we employ lean principles and agile processes in managing our business. This foundation of guiding values, combined with our entrepreneurial spirit, gives Anika the ability and fortitude to generate innovative ideas and to grow our portfolio of successful products.
Anika offers a broad spectrum of therapeutic treatments ranging from pain management and tissue regeneration to wound care and skin rejuvenation. Our proprietary technology is based on hyaluronic acid (HA), a naturally occurring polymer found throughout the body vital for proper joint health and tissue function. Our products include MONOVISC®, ORTHOVISC®, and ORTHOVISC® mini used in the treatment of osteoarthritis; HYVISC® used in the treatment of equine osteoarthritis; ELEVESS® cosmetic dermal filler with lidocaine; ANIKAVISC® viscoelastic for ophthalmic surgery; INCERT®-S anti-adhesion surgical gel; and next generation products for joint health, advanced wound care and other applications.
At Anika, we believe that an individual’s feelings about their age are driven by perceptions about the state of their body. Therefore, our products endeavor to help you feel younger and remain active by delivering safe, effective and minimally invasive treatments to manage pain, restore joint health and tissue function, and support wound healing.
Bedford, US
Size (employees)
122 (est)+15%
Anika Therapeutics was founded in 1992 and is headquartered in Bedford, US

Anika Therapeutics Office Locations

Anika Therapeutics has offices in Bedford and Ponte Fabbrica
Bedford, US (HQ)
32 Wiggins Ave
Ponte Fabbrica, IT
3 Via Ponte Della Fabbrica

Anika Therapeutics Metrics

Anika Therapeutics Financial Metrics

Anika Therapeutics's revenue was reported to be $103.4 m in FY, 2016 which is a 11% increase from the previous period.

Revenue (FY, 2016)

$103.4 m

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

$79.4 m

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

$32.5 m

EBIT (FY, 2016)

$50.6 m

Market capitalization (22-May-2017)

$686 m

Closing share price (22-May-2017)


Cash (31-Dec-2016)

$104.3 m
Anika Therapeutics's current market capitalization is $686 m.
FY, 2013FY, 2014FY, 2015FY, 2016


$75.1 m$105.6 m$93 m$103.4 m

Revenue growth, %


Cost of goods sold

$22.8 m$20.9 m$21.1 m$24 m

Gross profit

$52.3 m$84.7 m$71.9 m$79.4 m

Gross profit Margin, %


Operating expense total

$19.7 m$44.1 m$44.9 m$52.8 m


$32.6 m$61.4 m$48.1 m$50.6 m

EBIT margin, %


Interest income

$127.2 k$58.1 k$120 k$263 k

Pre tax profit

$32.5 m$61.5 m$48.3 m$50.9 m

Income tax expense

$11.9 m$23.2 m$17.5 m$18.3 m

Net Income

$20.6 m$38.3 m$30.8 m$32.5 m
FY, 2013FY, 2014FY, 2015FY, 2016


$63.3 m$100.2 m$110.7 m$104.3 m


$11 m$12.4 m$14.9 m$16 m

Current Assets

$94.6 m$139 m$176.4 m$170.4 m


$52.4 m$53.6 m$40.1 m$52.3 m


$9.4 m$8.3 m$7.5 m$7.2 m

Total Assets

$156 m$194 m$235.7 m$240.2 m

Accounts Payable

$2.8 m$1.2 m$8.3 m$2.3 m

Current Liabilities

$9.3 m$6 m$17.3 m$8.8 m

Additional Paid-in Capital

$70.6 m$77.5 m$81.7 m$61.7 m

Retained Earnings

$66.6 m$104.9 m$135.7 m$168.2 m

Total Equity

$135.6 m$178.1 m$210.8 m$222.8 m

Financial Leverage

1.2 x1.1 x1.1 x1.1 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

$20.6 m$38.3 m$30.8 m$32.5 m

Depreciation and Amortization

$4.8 m$4.7 m$3.8 m$3.7 m

Accounts Receivable

$2.4 m$897.6 k($5 m)($6.2 m)


($2.8 m)($2 m)($2.9 m)($1.7 m)

Accounts Payable

$622.9 k($749.6 k)$5.6 m($5.1 m)

Cash From Operating Activities

$25.2 m$40 m$39.1 m$23.8 m

Purchases of PP&E

($440.9 k)($1.6 m)($9.2 m)

Cash From Investing Activities

($253.2 k)($8.3 m)($30.2 m)($6.8 m)

Cash From Financing Activities

($5.7 m)$5.3 m$1.9 m($23.3 m)

Interest Paid

$126 k$126 k

Income Taxes Paid

$9.8 m$13.8 m$12.7 m$22.8 m
Y, 2016

Financial Leverage

1.1 x

Anika Therapeutics Operating Metrics

FY, 2016

Patents Licensed


Patents Pending


Patents (US)


Patents (foreign)


    Anika Therapeutics Market Value History

    Anika Therapeutics Online Presence

    Anika Therapeutics Company Life

    You may also be interested in